[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356474-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356474-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","indication-expansion-dynamics-and-trial-characteristics-of-novel-multi-indication-anti-cancer-drugs-in-china-20002024-a-cross-sectional-study","Indication Expansion Dynamics and Trial Characteristics of Novel Multi-Indication Anti-Cancer Drugs in China (2000–2024) - A Cross-Sectional Study","","A cross-sectional analysis examines indication expansion trends and pivotal trial characteristics of novel multi-indication anti-cancer drugs approved in China from 2000 to 2024. Review of 74 drugs covering 265 total indications used data from NMPA, CDE, NHSA, ClinicalTrials.gov, and package inserts. Results show most drugs support solid tumors, with immune checkpoint inhibitors demonstrating the broadest expansion, yet NRDL inclusion lagging market approval. Sequential approvals differed by treatment, approval type, arms, design, and single-arm endpoints.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/indication-expansion-dynamics-and-trial-characteristics-of-novel-multi-indication-anti-cancer-drugs-in-china-20002024-a-cross-sectional-study/356474/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/indication-expansion-dynamics-and-trial-characteristics-of-novel-multi-indication-anti-cancer-drugs-in-china-20002024-a-cross-sectional-study/356474.png","ImageObject",300,407,{"name":42,"@type":43},"Aurelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-17","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main purpose of the study?","Question",{"text":63,"@type":64},"To analyze how indications expanded over time and to characterize pivotal trial features of novel multi-indication anti-cancer drugs approved in China from 2000 to 2024.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the study conducted and what data sources were used?",{"text":68,"@type":64},"A cross-sectional review covered 74 drugs and 265 total indications, using information from NMPA, CDE, NHSA, ClinicalTrials.gov, and drug package inserts, followed by descriptive statistics and specified significance tests.",{"name":70,"@type":61,"acceptedAnswer":71},"Which drug class showed the greatest indication expansion, and what mismatch was observed?",{"text":72,"@type":64},"Immune checkpoint inhibitors showed the greatest expansion, reaching the most extensively approved drug with 14 indications; however, NRDL inclusion did not keep pace with market approval.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356474,1791455324,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Drug Design, Development and Therapy  \nOpen Access Full Text Article ORIGINAL RESEARCH  \nIndication Expansion Dynamics and Trial Characteristics of Novel Multi-Indication Anti-Cancer Drugs in China (2000–2024):  \nA Cross-Sectional Study  \nXiaoyi Chen 1 , Huan Li 1 , Shunlong Ou 2 , Zhisan He 1 , Dongni Zheng 1 , 3 , Jing Luo 4  \n,  \nQian Jiang 2  \n1Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, People’s Republic of China; 2Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, People’s Republic of China; 3Department of Pharmacy, The Fifth People’s Hospital of Chengdu, Chengdu, Sichuan, People’s Republic of China; 4Department of Pharmacy, The Second People’s Hospital of Yibin, Yibin, Sichuan, People’s Republic of China  \nCorrespondence: Qian Jiang, Email [jiangqian@scszlyy.org.cn](jiangqian@scszlyy.org.cn)  \n\n| Purpose: To perform a cross-sectional analysis of the indication expansion trends and pivotal trial features of novel multi-indication anti-cancer drugs approved in China from 2000 to 2024.\u003Cbr>Methods: We conducted a cross-sectional review of 74 novel multi-indication anti-cancer drugs approved by the National Medical Products Administration (NMPA) in China from 2000 to 2024, encompassing 265 total indications. Data were collected from multiple sources, including the NMPA, the Center for Drug Evaluation (CDE) of the NMPA, the National Healthcare Security Administration (NHSA), [ClinicalTrials.gov](ClinicalTrials.gov), and drug package inserts. Descriptive statistics and Fisher’s exact test (two-tailed) or the χ2-test with Monte Carlo simulation, were used to analyze indication and clinical trial characteristics across indication approval sequence. Results: Of the 74 drugs, 32 (43%) held two indications, 23 (31%) held three, and 19 (26%) held four or more. Solid tumors accounted for 80% of all indications, most commonly non–small cell lung cancer. Immune checkpoint inhibitors (ICIs) exhibited the greatest expansion, with the most extensively approved drug reaching 14 indications. However, the inclusion of these drugs in the National Reimbursement Drug List (NRDL) did not keep pace with their market approval. Sequential approvals across indications showed significant differences in treatment type (P\u003C0.001), NMPA approval type (P=0.008), trial arms (P=0.009), trial design (P=0.030), and single-arm endpoints (P\u003C0.001) .\u003Cbr>Conclusion: Regulatory reforms facilitated the approval of novel multi-indication anti-cancer drugs, although NRDL inclusion has not kept pace. Targeted therapies dominate, while ICIs, though fewer, show the broadest indication expansion. Most drugs are approved for two to three indications, mainly in solid tumors, and later approvals were associated with different regulatory pathways than earlier ones.\u003Cbr>Keywords: NMPA approval, multi-indication, indication expansion, targeted therapy, pivotal trial |\n| --- |\n| Introduction\u003Cbr>Cancer incidence and mortality rates have risen steadily in recent years. According to the 2024 data from the International Agency for Research on Cancer (IARC) (GLOBOCAN), nearly 20 million new cancer cases and 9.74 million cancer deaths were reported globally in 2022.1 By 2050, the number of new cases is projected to reach 35 million. In Asia, cancer incidence and mortality account for 49.2% and 56. 1% of the global total, respectively.1 Notably, China reports the highest number of cases, with approximately 4.825 million new cancer cases and 2.574 million deaths in 2022, reflecting a continuous upward trend in both incidence and mortality rates compared to historical data.2 In light of the alarming rise in cancer incidence and mortality worldwide, the urgent need for more |\n\n","cbCaikyeY74a9hTf","https://ap.wps.com/l/cbCaikyeY74a9hTf","pdf",1940608,17,"English","# Purpose\n# Methods\n## Data sources\n## Statistical analysis\n# Results\n# Conclusion\n# Keywords\n# Introduction","[{\"question\":\"What was the main purpose of the study?\",\"answer\":\"To analyze how indications expanded over time and to characterize pivotal trial features of novel multi-indication anti-cancer drugs approved in China from 2000 to 2024.\"},{\"question\":\"How was the study conducted and what data sources were used?\",\"answer\":\"A cross-sectional review covered 74 drugs and 265 total indications, using information from NMPA, CDE, NHSA, ClinicalTrials.gov, and drug package inserts, followed by descriptive statistics and specified significance tests.\"},{\"question\":\"Which drug class showed the greatest indication expansion, and what mismatch was observed?\",\"answer\":\"Immune checkpoint inhibitors showed the greatest expansion, reaching the most extensively approved drug with 14 indications; however, NRDL inclusion did not keep pace with market approval.\"}]","Indication Expansion Dynamics and Trial Characteristics of Novel Multi-Indication Anti-Cancer Drugs in China (2000–2024) - A Cross-Sectional Study | PDF",1790125500,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b7449922be39f5979d621cb1deffe9e2.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/195f0f306d6901e49f7e9a76d1bc294a.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b4b3f4f5448f2fa257d85edfea4ca363.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0362c04f55d45881f45e61d06753b3d6.webp",980,1268]